3 Volatile Large-Cap Hemp Stocks to Watch for 2022
Given ever-present market volatility, it’s become pretty clear that investing in cannabis and hemp stocks is a long-term play. There are several fundamental issues impacting the cannabis industry which will mean hemp stocks are expected to remain volatile in the near-term. Cannabis investors must remain vigilant about where to allocate their investments. There are times when even large-cap firms lack healthy business models and their long-term prospects look dim. However, there are still several exciting large-cap hemp stocks to consider investing in. What are the 3 volatile large-cap hemp stocks to watch for 2022?
Related: Algorithmic Stock Trading Volatile Marijuana and Hemp Stocks
Most cannabis companies are struggling with their overall business models as well as substantial profitability issues. Even if the company has immense growth opportunities, everything boils down to the bottom-line. And if they are far from offering returns to the investors, these pot stocks are best avoided – for now. Let’s discuss three such leading cannabis companies that are facing tremendous selling pressure are discussed below.
Aurora Cannabis: Pricing issues and lack of profitability pose a major threat
[stock_market_widget type=”chart” symbol=”ACB” chart=”line” range=”1y” interval=”1d” line-color=”rgb(0, 128, 0)”]
Aurora Cannabis (NYSE: ACB) is a large-cap hemp stock that has historically not seen a favorable response from investors and the latest quarterly results were certainly no exception. It is pretty evident now that the company is struggling to find it’s footing. It’s far from a break-even point and its financials are under significant pressure.
Related: Aurora Cannabis Launches its First Medical CBD Product in Uruguay
Moreover, Aurora is burdened with debt. The company has over CA$400 million of total debt due by 2024, but it’s EBITDA is still negative. At the end of the last quarter, its cash balance stood at CA$120 million which is inadequate to service this quantum of debt or finance it’s growth endeavors – especially since its burning cash at such an unsustainable rate. The hemp stock is also flooding the market with more equity and diluting shareholder value. In the last quarter, it’s stock issuance was north of CA$100 million.
The marijuana company’s road to profitability is also rocky. The Canadian cannabis market is dealing with oversupply issues and prices have hit rock bottom. While Aurora did receive a positive response to its Cannabis 2.0 products, there is immense competition in the market. Due to pricing pressure, the pot company will not be able to hit a very high threshold of revenue. In fact, it may have to sell at a loss.
Not to mention the legalization of recreational marijuana for many countries is still in limbo. Unless Aurora solves it’s financial woes or finds a partner with deep pockets, it will continue to face this selling pressure.
Related: Investing in Volatile Hemp and Cannabis Stocks? Use Algorithmic Trading to Beat the Market
Canopy Growth: Weak financials stoke ongoing investor concerns
[stock_market_widget type=”chart” symbol=”CGC” chart=”line” range=”1y” interval=”1d” line-color=”rgb(0, 128, 0)”]
Canopy Growth (NYSE:CGC) is another mainstream cannabis stock that is witnessing increased sell-off and has already plunged over 12% in August, after mixed Q1 results.
The company’s revenue grew by just over 2% compared to the fourth quarter. On the other hand, nationwide cannabis retail sales in Canada rose 17% QoQ amid the pandemic. When we view Canopy’s revenue against this number, it is very meager – causing plenty of concern for the investors. Like Canopy, most pot companies are anyways struggling with profit and, if the revenue numbers aren’t as strong, growth investors start to panic.
Margins continue to be a cause for concern for Canopy. In the first quarter, the company’s gross margin rose to 7.1%, compared to 5% in the same period last year. The company aims to achieve a 40% gross margin which seems far-fetched at this point.
Is there any upside to an investment in Canopy Growth? The large-cap hemp stock has posted a narrower loss in Q1 due to aggressive cost-cutting. The cash burn rate also slowed during the period. Its partnership with Constellation Brands will help it withstand ongoing volatility and gain access to additional liquidity.
Related: MariMed Q1 2021 Results: Highest Core Cannabis Revenue and Profitability
However, Canopy Growth has a long way to go before it regains investor optimism in the near-term.
Tilray: Wider losses lead to selling pressure
[stock_market_widget type=”chart” symbol=”TLRY” chart=”line” range=”1y” interval=”1d” line-color=”rgb(0, 128, 0)”]
Tilray’s (NASDAQ:TLRY) latest results revealed that the cannabis company could be facing some serious trouble. In its second quarter, the pot producer’s net loss widened to $81.7 million compared to $36.3 million posted in the same period last year.
This raised investor concern and the stock plunged nearly 13% following the day. The loss increased primarily due to inventory write off and asset impairment charges. Though these are non-recurring charges – their quantum is significant.
Related: Is Tilray Stock a Buy?
On the revenue front, Tilray posted a 93% plunge in its bulk sales. The company indicated that it is moving away from bulk sales to focus on areas with better margin prospects. However, it is worth noting that Tilray’s international sales tripled in Q2.
It wouldn’t be correct to say that Tilray is in the doldrums. The company has a diversified business and its revenue isn’t dependent on a single stream. The financials were weak for the quarter and it surely makes it is a slightly riskier short-term investment for this large-cap hemp stock.
The Bottom Line
Hemp stocks have to ensure they improve profit margins before they run out of cash. As cannabis is illegal at the federal level in the U.S. raising debt capital remains an everpresent challenge. Raising equity capital results in investor dilutions. The cannabis segment can be compared to the dot com boom of 2000 which had multiple players at its peak but just a few survivors after the bloodbath was over.
Investors need to identify hemp companies that have a huge market presence and are focused on improving profitability which will give them ammunition to expand and hit profitability.
3 Volatile Large-Cap Hemp Stocks to Watch for 2022
Cannin Investment Group: Your Hemp Stocks Resource
Cannin is your #1 resource for hemp stocks. Our team of experts evaluates all hemp stock investing opportunities. We aggregate hundreds of hours of research to provide tips on the best hemp stocks for 2020.
Use Cannin as your resource for:
- Cannabis and hemp stocks & investing news
- Featured cannabis & hemp stocks analysis
- Comprehensive cannabis and hemp stock reports
Is it too late to invest in hemp stocks? No! This is the perfect time to invest.
Wall Street analysts expect the global cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in hemp stocks is now.
Are you interested in hemp stocks like GW Pharmaceuticals, Charlotte’s Web, Canopy Growth, or Hemp Inc.?
Are you looking to buy stock in hemp companies or marijuana companies in 2020? Are you looking for the best large-cap hemp stocks for 2020? Interested in emerging penny hemp stocks? Interested in leveraging the power of algorithmic stock trades to profit from hemp stocks? Looking for the best Canadian cannabis stocks to invest in? We can help.
Predict price movements of hemp stocks several hours in advance with our proprietary algorithmic stock trading software.
- +25% Gains in 2020
- +49.8% Gains in 2019
- Backtested since 2012
At Cannin, we’re so confident you’ll love our algotrading hemp stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.
Profit from the best hemp stocks – we’ll show you how at cannin.com.
